NCT07658196招募中1 期
TLR9 Immunotherapy for Peritoneal Carcinomatosis (TIPC) - Phase 1 Study of the Safety and Efficacy of ACM-CpG Intraperitoneal Injections for Treatment in Patients With Colorectal or Appendiceal Adenocarcinoma Peritoneal Metastases or Malignant Ascites
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 24
- 试验地点
- 2
研究概览
简要总结
The goal of this clinical trial is to determine the safety and efficacy of of ACM-CpG for inoperable peritoneal metastases or malignant ascites. The main questions it aims to answer are:
• To determine the safety and maximum tolerated dose (MTD) or optimal biologic dose (OBD) of intraperitoneal injection(s) of ACM-CpG for inoperable peritoneal metastases or malignant ascites? Researchers will assign treatment levels using escalating doses of ACM-CpG Therapy.
Participants will:
- Will receive at least one dose of ACM-CpG therapy on Day 1 of a 28-day treatment cycle.
- May receive up to 2 additional injections if they have clinically stable or responsive disease.
- Must visit the clinic on Days 1, 4, 7, 10, 14, 21, and 28 for checkups and tests.
- Will have a CT scan or MRI performed every 8 weeks for 3 scans and then continue to receive scans every 12 weeks to monitor their disease.
详细描述
Escalating doses of ACM-CpG Therapy will use a standard 3+3 design.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients eligible for inclusion in this study must meet all of the following criteria:
- •Male or female patients age ≥ 18 years of age at the time of informed consent
- •Must be able to provide written informed consent, stating an understanding of the procedures and investigational nature of the study treatment, and willingness to comply with study requirements
- •Must have documented CRC or appendiceal adenocarcinoma peritoneal carcinomatosis or malignant ascites. Primary tumor may be intact and limited liver and/or lung disease is permitted
- •Must have evaluable disease by physical examination, serum tumor markers, radiologic assessment, or laparoscopic visual assessment
- •Must have a life expectancy of ≥ 12 weeks as estimated by the investigator
- •Must have an ECOG status of ≤ 2
- •Patients with acceptable laboratory values defined as:
- •Estimated creatinine clearance (calculated using Cockcroft-Gault formula, or measured) ≥ 60 mL/min, not dialysis dependent
- •Total bilirubin ≤ 1.5 mg/dl, unless elevated bilirubin is clearly related to Gilbert syndrome (and total bilirubin < 6.0 mg/dl)
- •Alanine aminotransferase (ALT) ≤ 3.5 x upper limit of normal (ULN)
- •Aspartate aminotransferase (AST) ≤ 3.5 x ULN
- •Absolute neutrophil count > 1.0 x 109/L (must be independent of blood product administration)
- •Platelet count > 100 x 109/L (must be independent of blood product administration)
- •Hemoglobin ≥ 8 g/dL (must be independent of blood product administration)
- •Surgically sterile patients or patients of childbearing potential (CBP) who agree to use highly effective methods of contraception during study dosing and for 6 months after last dose of study drug
- •All other relevant medical conditions must be well-managed and stable, in the opinion of the investigator, for at least 28 days prior to administration of study drug
排除标准
- •Has received prior TLR9 therapy
- •Has received chemotherapy, radiotherapy, or biological cancer therapy within 21 days or 5 half-lives (whichever is shorter) of the start of treatment
- •Has received an investigational agent within 28 days of the start of treatment
- •Has received a commercial vaccine (flu, COVID, etc.) within 2 weeks of C1D1
- •Has any unresolved toxicity ≥ Grade 2 from previous anti-cancer therapy, except for stable chronic toxicities (≤ Grade 3) that are not expected to resolve
- •Has a history of histologically confirmed metastases outside of the peritoneal cavity, liver, or lungs
- •Has high volume liver or lung metastases, defined as > 50% replacement of the liver volume by metastatic disease or > 5 lung lesions greater than 1 cm in size
- •Tumor causing biliary obstruction not amenable to stenting or percutaneous drainage
- •Ongoing or untreated intra-abdominal infection or bowel obstruction
- •Has known, clinically active Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), or Human Immunodeficiency Virus (HIV) (Note: Testing is not required)
- •Receiving continuous systemic corticosteroid therapy (≥ 10 mg/day of prednisolone or equivalent)
- •Clinically significant cardiac disease or impaired cardiac function, including any of the following:
- •A history of newly diagnosed transmural myocardial infarction, cerebral infarction, or pulmonary embolism within 6 months, except those approved by the medical monitor
- •A history of newly diagnosed deep vein thrombosis (DVT) within 3 months
- •Left ventricular ejection fraction (LVEF) < 50%
- •QTc >480 msec
- •Active bacterial, viral, or fungal infection: patients with ongoing use of prophylactic antibiotics, antiviral agents, or antifungal agents remain eligible as long as there is no evidence of active infection
- •Other active malignancy within 2 years excluding cutaneous squamous or basal cell carcinomas
- •Any medical condition that would, in the investigator's judgment, prevent the patient's participation in the clinical study due to safety concerns, compliance with clinical study procedures or interpretation of study results
- •History of hypersensitivity to TLR9 agonists
- •Pregnant, likely to become pregnant, or lactating women (where pregnancy is defined as the state of a female after conception and until the termination of gestation)
研究组 & 干预措施
ACM-CpG
Experimental
干预措施: ACM-CpG (Drug)
研究者
研究点 (2)
Loading locations...
相似试验
Unknown
1 期
U69 治疗难治 / 复发 T 淋巴母细胞白血病 / 淋巴瘤（T- ALL/LBL）的安全性和有效性的单臂、开放性的 I 期临床研究ChiCTR2500114272上海优卡迪生物医药科技有限公司
招募中
1 期
Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid TumorsNCT07387068Genmab121
招募中
1 期
An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII DeficiencyHemophilia AFactor VII DeficiencyHemophilia BNCT07644832Shanghai RAAS Blood Products Co., Ltd.76
招募中
1 期
An Open-Label, Phase I Clinical Trial of Super CAR-T With GPC3-Positive Advanced Hepatocellular CarcinomaAdvanced Hepatocellular Carcinoma (HCC)GPC3 Positive Hepatocellular CarcinomaNCT07493044Guangzhou FineImmune Biotechnology Co., LTD.15
Unknown
1 期
CAR19-BCMA 双靶点 CAR-T 治疗复发 / 难治性浆细胞肿瘤ChiCTR2500105773研究经费由河北泰禾春雨生物科技有限公司提供